Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/gastro/gox011 http://scihub22266oqcxt.onion/10.1093/gastro/gox011 C5421460!5421460!28533907     free     free     free       Gastroenterol+Rep+(Oxf) 2017 ; 5 (2): 90-103 Nephropedia Template TP {{tp|p=28533907|t=2017. Novel treatment options for portal hypertension |pdf=|usr=}}{{28533907}} gab.com Text Novel treatment options for portal hypertension JO: Gastroenterol Rep (Oxf) http://www.kidney.de/pget.php?&tw=1&pmid=28533907 #FOAvip Portal hypertension is most frequently associated with cirrhosis and is a major driver for associated complications, such as variceal bleeding, ascites or hepatic encephalopathy. As such, clinically significant portal hypertension forms the prelude to decompensation and impacts significantly on the prognosis of patients with liver cirrhosis. At present, non-selective ?-blockers, vasopressin analogues and somatostatin analogues are the mainstay of treatment but these strategies are far from satisfactory and only target splanchnic hyperemia. In contrast, safe and reliable strategies to reduce the increased intrahepatic resistance in cirrhotic patients still represent a pending issue. In recent years, several preclinical and clinical trials have focused on this latter component and other therapeutic avenues. In this review, we highlight novel data in this context and address potentially interesting therapeutic options for the future. Twit Text FOAVip Novel treatment options for portal hypertension ????Gastroenterol Rep (Oxf) http://www.kidney.de/pget.php?&tw=1&pmid=28533907 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28533907 #FOAvip English Wikipedia <ref>{{Cite pmid|28533907}}</ref> Novel treatment options for portal hypertension #MMPMID28533907 Schwabl P; Laleman W Gastroenterol Rep (Oxf) 2017[May]; 5 (2): 90-103 PMID28533907show ga Portal hypertension is most frequently associated with cirrhosis and is a major driver for associated complications, such as variceal bleeding, ascites or hepatic encephalopathy. As such, clinically significant portal hypertension forms the prelude to decompensation and impacts significantly on the prognosis of patients with liver cirrhosis. At present, non-selective ?-blockers, vasopressin analogues and somatostatin analogues are the mainstay of treatment but these strategies are far from satisfactory and only target splanchnic hyperemia. In contrast, safe and reliable strategies to reduce the increased intrahepatic resistance in cirrhotic patients still represent a pending issue. In recent years, several preclinical and clinical trials have focused on this latter component and other therapeutic avenues. In this review, we highlight novel data in this context and address potentially interesting therapeutic options for the future. äNovel treatment options for portal hypertension (epmc).pdf DeepDyve Pubget Overpricing